MindWalk(NASDAQ) IPA

Current PriceN/A

Market CapN/A

Since IPO (2017)-66%

5 Year-89%

1 Year-17%

1 Month-5%

MindWalk last closing stock price
Metric	Price	Date
Last close	USD 1.46	2026-07-21

MindWalk stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.35%	USD 1.48	2026-07-14
1 month	-4.58%	USD 1.53	2026-06-18
3 month	+12.31%	USD 1.30	2026-04-22
Year to date	-19.78%	USD 1.82	2025-12-31
1 year	-16.57%	USD 1.75	2025-07-21
3 year	-46.08%	USD 2.71	2023-07-21
5 year	-88.96%	USD 13.22	2021-07-22
Since inception	-66.35%	USD 4.34	2017-01-19

MindWalk Financials at a Glance

Market Cap

N/A

Revenue (TTM)

CA$18.40M

Net Income (TTM)

-CA$12.21M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Dec 10, 2025

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Dec 10, 2025

IPA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MindWalk

ImmunoPrecise Antibodies Ltd. specializes in the discovery and development of therapeutic antibodies, offering a comprehensive suite of services to pharmaceutical and biotechnology markets. Its proprietary platform integrates state-of-the-art technologies for accelerated and precise antibody generation.

Products and Services

Antibody discovery services for therapeutic development

Custom monoclonal and polyclonal antibody production

Characterization and optimization of antibodies for improved efficacy

Integrated preclinical solutions to expedite drug development

What Makes ImmunoPrecise Antibodies Ltd. Special

ImmunoPrecise differentiates itself through its advanced platform that combines innovative technologies and methodologies, enhancing the precision and speed of antibody discovery. Its approach contrasts with traditional firms by using cutting-edge technology rather than outdated or singular techniques.

Five Things You Need to Know

The company's leadership comprises seasoned professionals with extensive biotech and pharmaceutical expertise.

ImmunoPrecise's strategic partnerships diversify revenue and advance its goal in therapeutic antibody development.

The company emphasizes a scalable business model, broadening service offerings and expanding its global reach.

Its proprietary platform underpins its competitive advantage in accelerating antibody generation.

ImmunoPrecise aims to capitalize on the growing demand for antibody therapeutics, fostering long-term growth.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

102

CEO

Jennifer L. Bath, PhD

Website

www.ipatherapeutics.com

Headquarters

Austin, BC V8Z 7X8, CA

IPA Financials

Key Financial Metrics (TTM)

Gross Margin

60.32%

Operating Margin

-65.31%

Net Income Margin

-66.36%

Return on Equity

-63.24%

Return on Capital

-32.94%

Return on Assets

-52.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CA$11.10M

Operating Income

-CA$12.03M

EBITDA

-CA$10.19M

Operating Cash Flow

-CA$11.14M

Capital Expenditure

-CA$743.51K

Free Cash Flow

-CA$11.88M

Cash & ST Invst.

CA$14.18M

Total Debt

CA$3.55M

MindWalk Performance Analysis

MindWalk annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-04-30	CAD 15,432,731	N/A
2023	2023-04-30	CAD 15,545,096	0.7%
2024	2024-04-30	CAD 18,157,239	16.8%
2025	2025-04-30	CAD 17,596,293	-3.1%

MindWalk sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-04-30	13.5%
Q1	2025-07-31	-54.7%
Q2	2025-10-31	31.8%
Q3	2026-01-31	-1.8%

MindWalk annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-04-30	CAD -0.68	N/A
2023	2023-04-30	CAD -0.80	18.6%
2024	2024-04-30	CAD -0.75	-6.0%
2025	2025-04-30	CAD -0.65	-13.9%

MindWalk sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-04-30	90.1%
Q1	2025-07-31	1.5%
Q2	2025-10-31	-8.7%
Q3	2026-01-31	-18.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

CA$4.09M

-33.5%

Gross Profit

CA$2.42M

-26.4%

Gross Margin

59.26%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-CA$3.87M

+82.0%

EBITDA

-CA$3.40M

+85.2%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

CA$14.18M

+9.8%

Total Debt

CA$3.55M

-72.5%

Accounts Receivable

CA$3.03M

-37.7%

Inventory

CA$493.83K

-74.3%

Long Term Debt

CA$3.12M

-72.2%

Short Term Debt

CA$430.33K

-84.9%

Return on Assets

-52.58%

N/A

Return on Invested Capital

-66.24%

N/A

Free Cash Flow

-CA$2.96M

-124.8%

Operating Cash Flow

-CA$2.93M

-143.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IGMSIGM Biosciences, Inc.

IGMSIGM Biosciences, Inc.$1.27+0.00%

JBIOJade Biosciences, Inc.

JBIOJade Biosciences, Inc.$20.53+4.37%

QNCXQuince Therapeutics, Inc.

QNCXQuince Therapeutics, Inc.$18.78-0.21%

LABPLandos Biopharma, Inc.

LABPLandos Biopharma, Inc.$22.93+0.57%

SURFSurface Oncology, Inc.

SURFSurface Oncology, Inc.$1.07-0.93%

BLIBerkeley Lights, Inc.

BLIBerkeley Lights, Inc.$1.20-5.88%

RPHMReneo Pharmaceuticals, Inc.

RPHMReneo Pharmaceuticals, Inc.$18.20+952.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$7.66+0.11%

PATHUiPath

PATHUiPath$12.04-0.01%

TAT&T

TAT&T$22.26+0.01%

INTCIntel

INTCIntel$105.45+0.09%

NOKNokia

NOKNokia$10.63+0.05%

MARAMara Holdings

MARAMara Holdings$12.25+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.28+0.01%

Questions About IPA

What is the current price of MindWalk?

MindWalk is trading at N/A per share.

What is the 52-week range for MindWalk?

Over the past 52 weeks, MindWalk has traded between N/A and N/A.

How much debt does MindWalk have?

As of the most recent reporting period, MindWalk reported total debt of CA$2.60M.

How much cash does MindWalk have on hand?

MindWalk reported CA$10.39M in cash and cash equivalents in its most recent financial results.

What is MindWalk’s dividend yield?

MindWalk does not currently have a dividend yield.

MindWalk(NASDAQ) IPA

MindWalk Financials at a Glance

IPA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MindWalk

Products and Services

What Makes ImmunoPrecise Antibodies Ltd. Special

Five Things You Need to Know

IPA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MindWalk Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IPA

What is the current price of MindWalk?

What is the 52-week range for MindWalk?

How much debt does MindWalk have?

How much cash does MindWalk have on hand?

What is MindWalk’s dividend yield?

Premium Investing Services